Episode 20. Management of Myeloma in LMICs
Blood Cancer Talks
The Problem With VRD Induction in the Public Setting
In most places they don't have access to PIs in the first line, even in the largest insurance government type coverage. They still don't use Bortezomide as a first line treatment. It's a big problem. We recently did a review of who are the editors of hematology journals and these are all journals from high income countries. So that means that most of the top science is for only the US, North America and Europe. You might argue that we should develop our own guidelines and our own data to guide our therapy. But do we have the research capacity to do that? Our guidelines are going to be of high quality. These are the kind of things I
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
